Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?

Immunome, Inc. (NASDAQ:IMNM) is among the 14 best booming stocks to buy right now. The company’s shares are surging and have gained 48% in the last three months.

Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels

The returns have been driven primarily by bullish outlooks on the stock’s potential to treat desmoid tumors.

On December 15, Immunome, Inc. (NASDAQ:IMNM) shared positive topline results from the Phase 3 RINGSIDE trial, demonstrating an improved survival rate without progression, when compared with a placebo. The results showed the drug decreased the likelihood of death or disease progression by 84%.

According to the company’s press release, 156 patients were part of the trial, of which about 56% of them had their tumors disappear or shrink in size, in contrast with 9% on placebo. Based on the results, Immunome, Inc. (NASDAQ:IMNM) said it plans on seeking approval from the FDA for Varegacestat in the second quarter of 2026.

Following the results, Guggenheim, on December 22, revised its price target on the stock to $35 from $25, while keeping a Buy rating on the shares. The research firm expects approval for Varegacestat from the FDA and says the drug could grab a major chunk of the share in America’s desmoid tumors market.

Evercore ISI Group and Lake Street also lifted their price targets on Immunome, Inc. (NASDAQ:IMNM) to $40 from $18, and $32 from $22, while reiterating their Outperform and Buy ratings, respectively.

Wall Street analysts have a consensus Strong Buy rating on the stock, with a one-year average share price target of $33.20, representing an upside potential of 61.40%, as of January 12.

Immunome, Inc. (NASDAQ:IMNM) is an oncology company that develops treatments and therapies for cancer patients.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.